GU CONNECT expert, Prof. Gert Attard provides a GU cancer update from ESMO 2020 for you.
GU cancer update by Prof. Gert Attard, University College London Cancer Institute, UK
GU CONNECT expert, Prof. Gert Attard provides a GU cancer update from ESMO 2020 for you.
GU cancer update by Prof. Gert Attard, University College London Cancer Institute, UK
Prof. Attard is a Cancer Research UK Clinician Scientist and Team Leader at The Institute of Cancer Research and an Honorary Medical Oncology Consultant at the Royal Marsden NHS Foundation Trust, London, UK. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010. His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration-resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and a co-author of more than 100 peer-reviewed manuscripts, including several important papers on advanced prostate cancer. Prof. Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investor Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. Prof. Attard sits on a number of advisory boards and the editorial board of Annals of Oncology.
Grants or contracts from Astellas Pharma, Blue Earth Therapeutics, Janssen, Veracye and Novartis
Consulting fees from Amgen, AstraZeneca, Astellas Pharma, Bayer, Blue Earth Therapeutics, Janssen-Cilag, Merck & Co, Merck Sorono Ltd, Novartis, Pfizer, Veracyte.
Payment or honoraria from Astellas Pharma, Janssen, Astrazeneca, Sanofi, Sandoz.
Support for attending meetings/travel from Amgen, Astellas Pharma, Bayer, Janssen, Merck Sorono Ltd, Pfizer
On the Institute of Cancer Research Discoveries list of abiraterone acetate. Listed as inventor on docetaxel predictive, biomarker (Veracyte).
Listed as inventor on patent related to blood biomarkers (UCL, Cancer Research Horizons)
Commercial agreements with employer, UCL with Artera and Veracyte
Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO
Expert opinion on the latest practice-changing data
Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer
Experți de renume din domeniul medical își împărtășesc perspectivele. Navigați în secțiuni pentru a selecta un episod al podcastului
Improving the survival of patients with relapsed/refractory multiple myeloma